Erythropoietin (EPO) is a 165-amino-acid glycoprotein hormone — four antiparallel α-helices in the cytokine fold, ~40% of its mass N- and O-linked carbohydrate — released by the kidney's peritubular fibroblasts when tissue oxygen falls, to drive red-cell production in the marrow. This page covers the protein and its receptor; the hormone's physiology (hypoxia sensing via HIF, the feedback loop, clinical anemia use) is treated on the canonical erythropoietin hormone page. As a protein it is biotechnology's classic glycoprotein: the carbohydrate dictates half-life and activity, and the engineered ESA family (darbepoetin, peginesatide's mimic, EPO-Fc) is glycoengineering in practice.
The protein core is the short-chain four-helix-bundle cytokine fold; the receptor-binding faces (site 1 and site 2) engage two EPOR molecules — a pre-dimered receptor pulled into the signalling geometry.
Glycosylation is the pharmacology: sialylated branches extend half-life from minutes (unglycosylated) to hours; hyperglycosylated darbepoetin stretches it further.
The 1985 cloning and 1989 recombinant approval (epoetin alfa) were the anemia-therapy revolution — and the doping scandal that followed elite endurance sport.
Function
Receptor signalling: EPO → EPOR → JAK2 → STAT5 (and PI3K-AKT, see Akt, and MAPK) — survival and proliferation of erythroid progenitors; the CFU-E stage is the physiologic target.
Non-erythroid roles: EPOR expression in brain, heart, and endothelium suggests tissue-protection functions — the neuroprotective research program (and negative stroke trials).
Iron coupling: increased erythropoiesis consumes iron; hepcidin coordinates the two — functional iron deficiency limits EPO's effect.
Regulation
HIF-2α binds the EPO gene's hypoxia-response element; prolyl-hydroxylation of HIF (oxygen-dependent) is the oxygen sensor — the pathway the 2019 Nobel physiology prize recognised.
Feedback: rising hematocrit restores oxygen, HIF degrades, EPO transcription falls — levels swing a thousand-fold between anemia and polycythemia.
HIF stabilisers (roxadustat) induce endogenous EPO — the oral alternative to injected ESAs.
Interactions
JAK2's downstream STAT5 is the lineage signal — see STAT family signalling; SOCS proteins are the feedback brake.
With transferrin's iron delivery: the erythroid program needs both the mitogen and the metal.
Anti-EPO antibodies (pure red-cell aplasia, from some ESA formulations) are the therapy's rarest and sharpest complication.